NAS
KYMR icon

Nykredit A/S’s Kymera Therapeutics KYMR Stock Holding History

Nykredit A/S’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$207K Buy
+1,807
New +$155K ﹤0.01% 1018

Other funds holding KYMR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

Nykredit A/S's KYMR Position: Q2 2026 in Review

Nykredit A/S opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 1,807 shares worth $207K. The stake represents ﹤0.01% of the portfolio and ranks #1018 among its holdings.

190 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Nykredit A/S held 1,807 shares of Kymera Therapeutics worth $207K as of Q2 2026.
  • Kymera Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1018 holding.
  • 190 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.